Background/aims: In clinical trials with time-to-event outcomes, usually the significance tests and confidence intervals are based on a proportional hazards model. Thus, the temporal pattern of the treatment effect is not directly considered. This could be problematic if the proportional hazards assumption is violated, as such violation could impact both interim and final estimates of the treatment effect. Methods: We describe the application of inference procedures developed recently in the literature for time-to-event outcomes when the treatment effect may or may not be time-dependent. The inference procedures are based on a new model which contains the proportional hazards model as a sub-model. The temporal pattern of the treatment effect can then be expressed and displayed. The average hazard ratio is used as the summary measure of the treatment effect. The test of the null hypothesis uses adaptive weights that often lead to improvement in power over the log-rank test. Results: Without needing to assume proportional hazards, the new approach yields results consistent with previously published findings in the Systolic Blood Pressure Intervention Trial. It provides a visual display of the time course of the treatment effect. At four of the five scheduled interim looks, the new approach yields smaller p values than the log-rank test. The average hazard ratio and its confidence interval indicates a treatment effect nearly a year earlier than a restricted mean survival time-based approach. Conclusion: When the hazards are proportional between the comparison groups, the new methods yield results very close to the traditional approaches. When the proportional hazards assumption is violated, the new methods continue to be applicable and can potentially be more sensitive to departure from the null hypothesis.
Background
The Systolic Blood Pressure Intervention Trial (SPRINT) was designed to determine whether treating blood pressure to a target systolic pressure of \120 mm Hg (intensive treatment) is superior to treating to the commonly recommended target of \140 mm Hg (standard treatment). 1 The primary outcome is the first occurrence of a myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular disease death. The intervention was stopped early for efficacy due to a significant reduction in the rate of the primary outcome, with hazard ratio 0.75 (95% confidence interval (CI): 0.64-0.89; p \ 0.001). Death from any cause was also significantly lower in the intensive treatment group, with hazard ratio 0.73 (95% CI: 0.60-0.90; p = 0.003).
In clinical trials for time-to-event-data such as SPRINT, the hazard ratio is the most common measure of treatment effect. Estimation of the hazard ratio is often based on the Cox proportional hazards model. 2 For testing the existence of a treatment effect, the log-rank test is widely used. 3 It is (asymptotically) optimal under proportional hazards alternatives, with equal censoring patterns in the two groups. Other tests based on the two sample Cox proportional hazards model, such as the score test and the likelihood ratio test, are asymptotically equivalent to the log-rank test under the null hypothesis. 4 When the hazards are non-proportional, the maximum partial likelihood estimator approximates a quantity that can be viewed as a weighted average of the hazard ratios in the different follow-up periods with weights depending on the censoring pattern. 5, 6 While in most applications the proportional hazards model provides good approximations, there are situations in which the time-dependence of hazard ratio plays a critical role in explaining the outcomes, such as in the Women's Health Initiative estrogen plus progestin trial and observational studies. 7 For SPRINT, 1 although the proportional hazards model gives a reasonable fit, the Kaplan-Meier curves for the primary outcome and all-cause mortality remain close for the first year or the first 2 years, respectively, and then gradually start to diverge. This indicates that it may take time for the effect to develop. A modeling and inference approach that allows possibly varying hazard ratios should more accurately characterize the temporal effect of the treatment course, and therefore might provide more precise estimates of the effect of the SPRINT intervention.
Here, we describe an approach for designing and analyzing time-to-event trials using the short-term and long-term hazard ratio model developed by Yang and Prentice. 8 This approach is more flexible than the traditional approach, as it allows non-proportional hazards as well as proportional hazards. Thus, it may provide useful insights into the temporal aspects of the treatment effect and yield more accurate estimation and more powerful test of the treatment effect.
Methods
The short-term and long-term hazard ratio model Label the two groups control and treatment, with hazard functions l C (t), l T (t), respectively. The Cox proportional hazards model assumes that l T (t) = ul C (t), where l C (t) is unspecified and u.0. It follows that l T (t)=l C (t) = u. For the Cox model, the (constant) hazard ratio completely describes the group difference, and thus has been the most popular measure of the treatment effect.
The short-term and long-term hazard ratio model postulates that
where
is the survival function of the control group, t 0 = supft : S C (t).0g and u 1 , u 2 are positive constants.
Under this model, the hazard ratio between the two groups is time-dependent, given by
which depends on u 1 , u 2 , and S C (t). This ratio is monotone, increasing if u 2 .u 1 and decreasing if u 1 .u 2 . It depends on two scalar parameters u 1 , u 2 and the function S C (t) which is unspecified rather than a specified parametric function such as exp (À u 3 t u 4 ). This makes the model more flexible.
Since the hazard ratio approaches the values u 1 and u 2 , respectively, as t tends to zero or the upper limit of the data range, when there is no censoring, u 1 and u 2 can be interpreted as the short-term and long-term hazard ratios, respectively.
The short-term and long-term hazard ratio model contains the Cox proportional hazards model and the proportional odds model as two sub-models corresponding to u 1 = u 2 and u 2 = 1, respectively. In addition, the model accommodates other patterns of the treatment effect, such as those corresponding to no initial effect or crossing hazard (survival) functions.
Let R(t) = 1=S C (t) À 1 and b j = log (u j ), j = 1, 2. Model (1) can be re-expressed in terms of the three parameters b 1 , b 2 , and R(t). In the pseudo-likelihood approach to estimating the model parameters, R(t) was replaced in the score function of (b 1 , b 2 ) by a datadependent functionR(t; b) of b = (b 1 , b 2 ). The zero of the resulting function is then obtained as the pseudolikelihood estimatorb of b and R(t) is estimated bŷ R(t;b). 8 For checking goodness-of-fit of model (1), two omnibus tests have been developed. 9 
Displaying the temporal treatment effect
Under model (1) re-expressed in terms of b 1 , b 2 , and R(t), the hazard ratio h(t) = l T (t)=l C (t) can be written as
An estimator b h(t) can be obtained usingb andR(t;b). Based on the asymptotic normality of b h(t), at a specific t 0 2 D, where D is the follow-up range, a 95% CI ('(t 0 ), u(t 0 )) for the hazard ratio h(t 0 ) can be obtained. 10 That is
where ffi indicates ''is asymptotically equal to.'' Plotting these point-wise CIs for t 0 2 D will give us a display of the temporal trend of the treatment effect.
Since the hazard ratio may not be a constant, it is desirable to have a stronger probability statement than equation (4) . A confidence band, or simultaneous CIs, (L(t),Û(t)), t 2 D, satisfies a single probability statement
Yang and Prentice 10 developed such confidence bands for h(t) and recommended the so-called equal precision band. The CIs and the confidence band give a temporal display of the treatment effect pattern. More discussions and comparison with related works such as the non-parametric method of Gilbert et al. 11 can be found in Yang and Prentice. 10 Average hazard ratio as the summary measure of treatment effect After h(t) is obtained under model (1) , to summarize the treatment effect, a simple way is to use the average hazard ratio AHR t = Ð t 0 h(t)dt=t, where t is a fixed time point less than or equal to t 0 , the maximum follow-up duration. This is the same as the usual hazard ratio if the proportional hazards assumption is met. A desirable property of the average hazard ratio is that it permits a simple extension to adjust for covariates. 12 The average hazard ratio depends on the range ½0, t. A subset of the range can also be considered. To obtain a summary measure for the overall study, we recommend taking t = t 0 . Due to data sparsity near the end of the trial, some may advocate choosing t to be, say, 6 months less than t 0 . No matter how t is chosen; it needs to be clearly specified in the protocol. The importance of specifying the limit of the length of follow-up has been noted in the literature. 6 
Testing the null hypothesis
The log-rank test has been very popular for testing treatment effect with time-to-event outcome trials due to its optimality under a proportional hazards alternative hypothesis. For a specific non-proportional alternative hypothesis, a weighted log-rank test can be used, with the weight chosen appropriately to maximize the power. For example, the Peto-Prentice test 13 and in general the G r, g test of Fleming and Harrington 14 can be recast as weighted log-rank tests. In practice, it is difficult to predict which alternative hypothesis best matches the actual data pattern. Thus, a popular approach is to design a test with good power over a range of possible alternative hypotheses. Examples include the linear combinations and maximum of a class of standardized tests. [15] [16] [17] [18] Typically, such tests maintain good power under a range of non-proportional hazards alternatives. However, the trade-off is that usually these tests will no longer be optimal under proportional hazards alternatives.
Yang and Prentice 19 developed an adaptively weighted log-rank test. A significant feature of the test is that it remains optimal under proportional hazards alternatives. When the hazards are non-proportional, the adaptive weights typically lead to improvement in power over the log-rank test. Specifically, the test uses the weights b h(t) and 1= b h(t), where b h(t) is the estimated hazard ratio function under model (1) . To control the potentially inflated test size for small samples, an adjustment was made to take into consideration the correlation between the relevant statistics.
All the previously mentioned methodologies on displaying temporal treatment effect pattern, average hazard ratio, goodness-of-fit tests, and the adaptively weighted log-rank test have been rigorously justified and studied via simulation studies and real data applications. We refer the readers to relevant references for more descriptions and discussions.
Interim monitoring boundaries
Typically, clinical trials are monitored periodically by a data safety and monitoring board that is charged in part to stop the trial early if there is strong interim evidence for efficacy or harm. In the Lan-DeMets spending function approach, 20 a spending function a(t) is used which monotonically increases from a(0) = 0 to a(1) = a as the information fraction t, the proportion of the number of events at the interim time relative to the total expected number of events, goes from 0 to 1. Assume that the monitoring times correspond to information times t 1 , . . . , t L . LetT j be the test statistic at the jth interim look. Then, to protect the overall type I error of the trial, the critical values c ' are obtained such that
The allocated a is a(t 1 ) at the first look, and
It is beyond the scope of this article to extend the adaptively weighted log-rank test to the interim analysis setting and investigate the properties through simulations and applications. Here, for illustrative purpose, we use a conservative Bonferroni approach. Let the critical values c Ã j be such that
Then the null hypothesis is rejected ifT ' exceeds the critical value at an interim look ' L or, equivalently, if the p value at the 'th look is less than the allocated a for some ' L. This conservative approach controls the overall size to be a. Typically, for this procedure, the loss of power is small if the spending function takes very small values at early looks. 21 We will see in the next section that the loss of power is minimal for the SPRINT primary outcome interim data. More discussions and references on interim analysis can be found in Proscahn et al. 21 and Jennison and Turnbull. 22 
Results

Background
Between 11 November 2010 and 15 March 2013, SPRINT recruited and randomized 9361 people. On 20 August 2015, the National Heart, Lung, and Blood Institute director accepted a recommendation from the data and safety monitoring board of the trial to inform the investigators and participants of the cardiovascularoutcome results after analyses of the primary outcome exceeded the monitoring boundary at two consecutive time points. The primary analysis compared the time to the first occurrence of a primary outcome event between the two study groups with the use of the intention-to-treat approach for all randomly assigned participants. Cox proportional hazards regression was used with two-sided tests at the 5% level of significance, with stratification by clinic site. Follow-up time was censored on the date of last event ascertainment.
Interim results
Interim analyses were performed for each meeting of the data and safety monitoring board, with group sequential stopping boundaries defined with an O'Brien-Fleming-type spending function. Before the SPRINT intervention was stopped early for efficacy, five interim analyses were conducted. For the particular spending function used in SPRINT, the amount of a allocated at the five looks are 1.09E-09, 1.0E-05, 0.00023, 0.00115, and 0.00396, respectively. Using the multiple testing procedure (7) withT ' , ' L, being the adaptively weighted log-rank test statistics, we would reject the null hypothesis of no treatment effect if the p value at any look is less than the allocated a at that look. Table 1 gives the p values of this conservative test at the five interim looks. For comparison, we also give the p values of procedure (7) withT ' , ' L, being the Wald test statistics from the average hazard ratio estimates at the interim looks. To obtain the estimated average hazard ratio at each interim look, t is chosen to be the last data point at that look. Included in the comparison are also the p values of procedure (7) with the log-rank test, and the p values of procedure (7) witĥ T ' , ' L, being the Wald test statistics based on the hazard ratio estimate under the proportional hazards assumption. From Table 1 , the adaptively weighted log-rank test, the Wald test based on the average hazard ratio, and the log-rank test reject the null hypothesis at the fourth and fifth looks, as the p values are less than the corresponding a allocated. We can also observe that for the LRAD: testing procedure (7) with the adaptively weighted log-rank test; AHR: testing procedure (7) with the Wald test from the average hazard ratio; LR: testing procedure (7) with the log-rank test; HR: testing procedure (7) with Wald test from the conventional constant hazard ratio estimate; critical value c Ã : critical values for the testing procedure (7) with the log-rank test; and critical value c: critical values for the usual testing procedure (6) with the log-rank test.
last four interim looks, the adaptively weighted logrank test and the Wald test based on the average hazard ratio yield more extreme p values than the log-rank test.
Note that if one uses procedure (7) withT ' being the Wald test statistics based on the hazard ratio estimate obtained under the proportional hazards assumption, from Table 1 , the p values are far from being significant not only at the first three looks but also at the fourth and fifth looks where the other three tests all yield p values less than the allocated a.
To assess how much inflation in critical value the approach in equation (7) would cause compared with the usual approach of equation (6), the last two rows of Table 1 also show the critical values for the log-rank test with equation (7), as well as the critical values of the log-rank test in the usual spending function approach based on equation (6) . It can be seen that the procedure in equation (7) gives critical values very close to those for the conventional procedure in equation (6) .
The confidence bands and average hazard ratios
For the primary outcome, SPRINT found a significant reduction of the composite event rate. The proportional hazards model assumes a constant hazard ratio over the data range and gives an estimated hazard ratio of 0.75, with 95% CI of 0.64-0.89. Although tests of proportionality are non-significant (p = 0.0934 for the primary outcome and p = 0.9329 for all-cause mortality), the Kaplan-Meier curves are nearly indistinguishable at the beginning, indicating a slow starting treatment process. For the primary outcome, the two goodnessof-fit tests 9 for model (1) have p values of 0.44 and 0.59, respectively. Applying model (1) to the SPRINT primary outcome, we obtain an estimated hazard ratio function b h(t) that starts from 0.94 at t = 0 and steadily decreases to 0.57 near the end of the trial. In Figure 1 , the confidence band, or simultaneous CIs, shows that the hazard ratio is less than 1 after a year into the trial. Let t = 4:78, which is the duration of the trial from November 2010 to August 2015. Then, the average hazard ratio is 0.70, with the 95% CI of 0.58-0.86, and a p value of 0.0006. For the secondary outcome of death from any cause, the estimated hazard ratio function b h(t) starts from 0.80 at t = 0 and steadily decreases to 0.64 near the end of the trial. The confidence band in Figure 2 shows more variation at both ends of the time scale, likely due to a smaller number of events compared with the primary outcome. With the same t = 4:78, the average hazard ratio is 0.72, with the 95% CI of 0.58-0.90, and a p value of 0.04.
For the other secondary outcomes, the estimated average hazard ratios and the 95% CIs are given in Table 2 . These outcomes were among the secondary outcomes pre-specified at the beginning of the trial and were pre-specified in the manuscript proposal of this article before access to the actual data. For comparison, SPRINT trial results are also included in Table 2 . The results with the average hazard ratio are very close to those in SPRINT trial, 1 although they tend to shift slightly downward.
Alternative approaches and extensions
For more stable results, t can be chosen to be less than the maximum follow-up duration. If t = 4:2, which is about 6 months less than the maximum follow-up duration, then the average hazard ratios and the CIs generally shift slightly upward. For example, the average hazard ratio for the primary outcome was 0.72, with 95% CI of 0.60-0.87. These small changes do not alter the conclusions in the previous section, and the results are omitted due to space limitations. Again t needs to be pre-specified.
As mentioned before, Wald test based on the average hazard ratio provides an alternative approach for testing the null. When the treatment effect is likely nonproportional, many other measures of the treatment effect have been proposed. Recently, the restricted mean survival time Ð t 0 S(t)dt and the restricted mean time lost t À Ð t 0 S(t)dt have been proposed. 23, 24 They have simple and intuitive interpretations and also permit a simple non-parametric estimation using the Kaplan-Meier estimators. When the event rate is low, the ratio of the restricted mean survival times of the two treatment groups is nearly one and thus not very informative. Here, we compare the average hazard ratio with the ratio of restricted mean time lost (rRMTL) for the primary outcome of SPRINT. The point-wise CIs for the average hazard ratio and rRMTL over ½0, t, for various values of t, are given in Figure 3 . The average hazard ratio indicates a treatment effect as early as 2.2 years into the study. It takes nearly a full year longer for the rRMTL to reflect a treatment effect. Similar observations also hold for other outcomes.
Another option for dealing with non-proportional hazards is given by the weighted Cox regression, which Table 2 . Average hazard ratio and hazard ratio for the primary and secondary outcomes in SPRINT (CKD and non-CKD refer to participants with or without chronic kidney disease at baseline, respectively). requires the assumption of covariate-independent censoring and uses inverse probability weighting in the estimating equation. 25 Similar to the average hazard ratio defined here, weighted Cox regression also requires specification of time range ½0, t. The weighted Cox regression estimate converges to an estimand that approximates the odds of concordance. For the SPRINT primary outcome, with t = 4:78, the weighted Cox regression estimate is 0.79, with 95% CI of 0.65-0.95 (p=0.020). However, the inverse probability weighting may cause unstable behavior of the estimate. This is the case for data at the third interim look. In Figure 4 , at various t, point estimates and 95% CIs are plotted for the average hazard ratio and the weighted Cox regression estimand. The average hazard ratio has stable point estimates and variance estimates with respect to the choice of t near the end of data range. In comparison, due to the use of inverse probability weight, the weighted Cox regression estimate is less stable and has variance that increases rapidly near the end of data range.
Xu and O'Quigley 26 considered inference on the average regression effect which provides yet one more approach to dealing with non-proportional hazards. The assumption of covariate-independent censoring is needed, and the estimating equation uses the reciprocal of the at-risk process. The average regression effect estimate converges to an estimand that approximates the logarithm of a geometric average hazard ratio. For the SPRINT primary outcome, the estimated geometric average hazard ratio is 0.79, with 95% CI of 0.65-0.97 (p=0.025).
Due to the availability of multiple approaches, as usual it is important to pre-specify the analysis plan in the trial protocol.
Sometimes, asymmetric interim monitoring boundary is preferred, with probability of early stopping due to harm higher than that due to efficacy. Since the adaptively weighted log-rank test can be adjusted for those one-sided situations, 19 the conservative approach in equation (7) can be extended correspondingly. Rigorous derivation of interim testing analogous to equation (6) will be pursued in the future.
In some clinical trials, there may also be interest in considering interim analysis for futility stopping, typically using the conditional powers. 27 Since the conditional power is typically computed under the null or a proportional alternative hypothesis, and the adaptively weighted log-rank test is asymptotically equivalent to the log-rank test under both null and proportional alternative hypotheses, a simple approach is to continue using existing methods based on the log-rank test, with inflation of type II error probability that can be assessed under a proportional alternative hypothesis. 27 Again, a rigorous development will be an important future research topic, especially when power under a non-proportional alternative is of interest.
Conclusion
For clinical trials with time-to-event outcomes, the most commonly used approach is CI estimation and hypothesis testing using a proportional hazards model. Here, we have described a more general and flexible approach based on model (1), which not only accommodates the usual proportional hazards situations but also permits many common patterns of non-proportionality. The average hazard ratio based on our proposed model reduces to the familiar hazard ratio if the hazards are proportional, and naturally extends the summary measure to non-proportional situations. The model-based hazard ratio estimates are also used in constructing the adaptively weighted log-rank test that improves the power of the conventional log-rank test. Whether or not the hazards are proportional, the confidence bands provide a useful visual tool for checking the temporal pattern of the treatment effect. For SPRINT, the average hazard ratio-based inference gives results very close to those under the proportional hazards assumption, and the confidence bands reveal a slowly starting time course.
In conclusion, when the proportional hazards assumption is valid, the new methods yield results very close to the traditional approaches. When the proportional hazards assumption is violated, the new methods continue to be applicable and offer greater flexibility and robustness over the traditional approaches that are based on the hazard ratio CI estimation and log-rank test. To implement the procedures, two R packages YPmodel and ClinicalTrialSummary have been developed and are available on The Comprehensive R Archive Network (CRAN).
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